Literature DB >> 9458141

Synchroneously occurring lung cancer (stages I-II) and coronary artery disease: concomitant versus staged surgical approach.

A J Voets1, K S Joesoef, M E van Teeffelen.   

Abstract

OBJECTIVE: The assessment of the best surgical approach in patients with synchroneously occurring lung cancer (stages I and II) and coronary artery disease: concomitant or staged.
METHODS: A retrospective, observational study was conducted in a tertiary centre for cardiothoracic surgery. From 1988-1995, 34 patients underwent pulmonary resection for stages I-II primary bronchogenic carcinoma and open-heart surgery (almost always coronary-artery bypass grafting), either concomitantly (n = 24) or in a staged procedure (n = 10). Mean interval between operations was 33.9 +/- 34.7 days (range: 12-120 days). Results were statistically computed.
RESULTS: Preoperatively both groups were perfectly matched. Follow-up was 100%. Long term survival, median 4.2 years, was comparable in both groups (log-rank test: chi2 0.30; df = 1; P = 0.58), indicating no influence on survival from performing either a concomitant or staged procedure. No relation could be demonstrated between survival and age, histopathology or extent of tumour; nor in the concomitantly operated group between survival and timing of lung resection in relation to extra-corporeal circulation. Overall peri-operative mortality was 6/34, 17.6%, but a large difference was noted between the two groups (5/24, 20.8% vs. 1/10, 10%; P = 0.64), underscoring the greater risk involved in the concomitant procedure, although this difference was not statistically significant because of small numbers.
CONCLUSIONS: No difference in survival between the two groups, one operated upon in a staged procedure, the other concomitantly, could be demonstrated. However, the greater perioperative risk makes the concomitant procedure less attractive, and the staged approach the preferred one. Interval between operations can be individualized according to the clinical status of the particular patient to a period as short as 2 weeks.

Entities:  

Mesh:

Year:  1997        PMID: 9458141     DOI: 10.1016/s1010-7940(97)00240-6

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Lung cancer resection with concurrent off-pump coronary artery bypasses: safety and efficiency.

Authors:  Xuchen Ma; Fangjiong Huang; Zhitai Zhang; Feiqiang Song; Songlei Ou
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

2.  Impact of previous cardiovascular surgery on postoperative morbidity and mortality after major pulmonary resection for non-small cell lung cancer.

Authors:  Ömer Senbaklavaci; Hakan Taspinar; Marc Hartert; Christian F Vahl
Journal:  Langenbecks Arch Surg       Date:  2013-06-13       Impact factor: 3.445

3.  Management and postoperative outcome in primary lung cancer and heart disease co-morbidity: a systematic review and meta-analysis.

Authors:  George D Bablekos; Antonis Analitis; Stylianos A Michaelides; Konstantinos A Charalabopoulos; Anastasia Tzonou
Journal:  Ann Transl Med       Date:  2016-06

4.  Perioperative outcomes of combined heart surgery and lung tumor resection: a systematic review and meta-analysis.

Authors:  Shizhao Cheng; Yiyao Jiang; Xin Li; Xike Lu; Xun Zhang; Daqiang Sun
Journal:  J Cardiothorac Surg       Date:  2021-08-09       Impact factor: 1.637

5.  Coronary artery bypass grafting with concomitant resection for carcinoma of lung.

Authors:  Yangyang Zhang; Yanhu Wu; Biao Yuan; Xiang Liu; Sheng Zhao; Zhi Li; Yu Xia
Journal:  J Biomed Res       Date:  2010-01

6.  [Combined surgical intervention treatments for lung cancer and coronary heart disease patients].

Authors:  Xuchen Ma; Zhitai Zhang; Yansheng Hu; Feiqiang Song; Shaoyan Zhang; Songlei Ou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.